x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243245
| Product Information | |
|---|---|
| CAS No. | 815619-12-6 |
| Formula | C25H31N2O6S+ |
| Molecular Weight | 487.59 |
| SMILES | O=C(N[C@H](C(N[C@@H](CCC(C[S+](C)C)=O)C(O)=O)=O)CC1=CC=CC=C1)OCC2=CC=CC=C2 |
| Target | Glutaminase, Apoptosis |
| Product Description | NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes. |
| Format & Storage | |
|---|---|
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
